Sheila A. Denton, EVP & General Counsel of Incyte Corporation (INCY), reported multiple transactions on 09/16/2025. The Form 4 shows a non-derivative acquisition of 278 shares of common stock at $64.25 and a non-derivative disposition of 278 shares at $83.15, leaving her with 33,200 shares beneficially owned after the sale. The filing also reports exercise of 278 employee stock options with a $64.25 exercise price, resulting in 278 underlying shares and total derivative holdings of 9,438 option-related shares exercisable through 07/14/2034. The filing discloses that 32,544 of the reported common shares are issuable under previously reported restricted stock units and earned performance units that have not vested.
Form 144 filing for Incyte Corp (INCY) discloses a proposed sale of 278 common shares by an insider through Morgan Stanley Smith Barney on 09/16/2025 with an aggregate market value of $23,115.70 and total shares outstanding listed as 195,276,145. The shares were acquired and paid for on 09/16/2025 via a stock option exercise with cash payment. The filer also reported six prior sales by the same person between 07/02/2025 and 09/02/2025, totaling 6,187 shares and gross proceeds shown for each trade.
Sheila A. Denton, EVP & General Counsel of Incyte Corp (INCY), reported insider transactions dated 09/02/2025. She exercised an employee stock option to acquire 598 shares at an exercise price of $58.06 and simultaneously sold 598 shares at $84.97. The Form 4 shows beneficial ownership amounts of 33,798 and 33,200 shares following the reported transactions, and notes that 32,544 shares are issuable from previously reported restricted stock units and performance units that have not vested. The filing indicates the transaction was made pursuant to a written plan consistent with Rule 10b5-1 and was signed on 09/04/2025 by an attorney-in-fact.
Form 144 notice for Incyte Genomics Inc (INCY): The filer reported a proposed sale of 598 common shares via Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of $50,812.06 and an approximate sale date of 09/02/2025. The shares were acquired the same day, 09/02/2025, by stock option exercise from the issuer and paid for in cash. The filer also disclosed six prior sales in the past three months totaling 7,384 shares for gross proceeds of $490,810.62 across dates from 06/03/2025 to 08/15/2025. The filer attests they are not aware of any undisclosed material adverse information.
Incyte Corp granted long‑term equity awards to its Executive Vice President of Human Resources consisting of 6,506 restricted stock units that vest 25% annually, 16,265 performance shares, and 29,230 stock options
Ramitpal K. Basi, serving as EVP, Human Resources of Incyte Corp (INCY), filed an initial Form 3 reporting the date triggering the filing as 08/25/2025. The filing states no securities are beneficially owned by the reporting person as of that date. The Form 3 shows the filing was executed on behalf of the reporting person by an attorney-in-fact, Elizabeth Feeney, with a signature date of 08/27/2025. This is a routine Section 16 initial ownership disclosure indicating the officer held no reportable shares or derivative positions at the event date.
Sheila A. Denton, EVP & General Counsel of Incyte Corp. (INCY), reported insider option activity under a written trading plan. The report shows Denton exercised 277 employee stock options with a $64.25 exercise price and simultaneously sold 277 shares at $86.81, leaving her beneficial ownership around 33,200 shares when including unvested restricted stock and performance units. The filing indicates an affirmative-defense trading plan consistent with Rule 10b5-1 and discloses remaining employee option holdings that become exercisable/vest under previously reported schedules.
Incyte Genomics Inc (INCY) filed a Form 144 reporting a proposed sale of 277 common shares on 08/15/2025 through Morgan Stanley Smith Barney LLC. The filing lists an aggregate market value of $24,046.37 and shows 195,276,145 shares outstanding, and the shares were acquired the same day via a stock option exercise with payment in cash.
The filing also discloses five recent sales by Sheila Denton within the prior three months: 1,795 shares on 06/03/2025; 599 on 07/02/2025; 3,330 on 07/15/2025; 785 on 07/16/2025; and 598 on 08/04/2025, with gross proceeds reported for each sale. The filer certifies no undisclosed material adverse information and the form identifies Morgan Stanley as broker of record.
Incyte Genomics' Form 144 records a proposed sale of 75,963 common shares through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $6,267,540.00. The shares were acquired via a stock option exercise on 08/13/2025 and payment was made in cash.
The filing also lists insider sales by Barry Flannelly totaling 27,472 shares in the past three months for gross proceeds of $2,040,893.53. The issuer reports 195,276,145 shares outstanding, so the proposed sale equals approximately 0.039% of outstanding shares. The document contains no earnings, guidance, or other operational details.
Incyte Genomics' Form 144 discloses a proposed sale of 14,037 common shares with an aggregate market value of $1,122,969.83, to be sold through Morgan Stanley Smith Barney on 08/12/2025 on NASDAQ. The filing states these shares were acquired on 08/12/2025 through a stock option exercise and paid for in cash.
The notice also lists recent sales by BARRY FLANNELLY totaling 13,435 shares in July 2025, generating gross proceeds of $917,923.70. The filing shows 195,276,145 shares outstanding and includes the filer's certification that they do not possess undisclosed material adverse information.